Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies

International Journal of Radiation Oncology Biology Physics

Volumn 54, Issue 5, 2002, Pages 1388-1396

  Brixey, Clark J ^a   Roeske, John C ^a   Lujan, Anthony E ^a   Yamada, S Diane ^a   Rotmensch, Jacob ^a   Mundt, Arno J ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Cervical cancer; Hematologic toxicity; Intensity modulated radiotherapy

Indexed keywords

BLOOD; CHEMOTHERAPY; COMPUTER SOFTWARE; GYNECOLOGY; HEALTH RISKS; IRRADIATION; TOXICITY;

HEMATOLOGIC TOXICITY;

RADIOTHERAPY;

CISPLATIN; HEMOGLOBIN;

ADULT; ARTICLE; BLOOD TOXICITY; BONE MARROW; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; FEMALE; HISTOGRAM; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; NEUTROPHIL; PELVIS; PELVIS LYMPH NODE; PRIORITY JOURNAL; RADIATION DOSE; THROMBOCYTE; UTERINE CERVIX CANCER; UTERUS; VAGINA;

AGED; BLOOD; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; RADIOTHERAPY, CONFORMAL; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; UTERINE CERVICAL NEOPLASMS; UTERINE NEOPLASMS;

EID: 0036890734     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)03801-4     Document Type: Article

References (49)

1. Cleaves M. Radium With a preliminary note on radium rays in the treatment of cancer . Med Rec. 64:1903;601-606.
2. Denis W., Martin C.L., Alderich M. A study of the relative toxic effects produced by regional radiation. Am J Med Sci. 160:1920;555-567.
3. Perez C.A., Breaux S., Bedwinek J.M., et al. Radiation therapy alone in the treatment of carcinoma of the uterine cervix. II. Analysis of complications. Cancer. 54:1984;235-246.
4. Roeske J.C., Mundt A.J., Halpern H., et al. Late rectal sequelae following definitive radiation therapy for carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 37:1997;351-358.
5. Keys H.M., Bundy B.N., Stehman F.B., et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 340:1999;1154-1161.
6. Rose P.G., Bundy B.N., Watkins E.B., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 340:1999;1144-1153.
7. Morris M., Eifel P.J., Tierney J.F., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 340:1999;1137-1143.
8. Green J.A., Kirwan J.M., Tierney J.F., et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix A systemic review and meta-analysis . Lancet. 358:2001;781-786.
9. Yang F.E., Vaida F., Ignacio L., et al. Analysis of weekly complete blood counts in patients receiving standard fractionated partial body radiation therapy. Int J Radiat Oncol Biol Phys. 33:1995;617-617.
10. Lhomme C., Fumoleau P., Fargeot P., et al. Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. J Clin Oncol. 17:1999;3136-3142.
11. Curtin J.P., Blessing J.A., Webster K.D., et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix A Gynecology Oncology Group Study . J Clin Oncol. 19:2001;1275-1278.
12. Mauch P., Constine L., Greenberger J., et al. Hematopoietic stem cell compartment Acute and late effects of radiation therapy and chemotherapy . Int J Radiat Oncol Biol Phys. 31:1995;1319-1339.
13. Ellis R.E. The distribution of active bone marrow in the adult. Phys Med Biol. 5:1961;255-263.
14. Thomas G. The effect of hemoglobin level on radiotherapy outcomes The Canadian experience . Semin Oncol. 28:(2 Suppl. 8):2001;60-65.
15. Kavanagh B.D., Fischer B.A., Segreti E.M., et al. Cost analysis of erythropoietin versus blood transfusions for cervical cancer patients receiving chemoradiotherapy. Int J Radiat Oncol Biol Phys. 51:2001;435-441.
16. Zanetta G., Lissoni A., Pellegrine A., et al. Neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel for locally advanced squamous cell cervical cancer. Ann Oncol. 10:1999;1171-1174.
17. Piver M.S., Ghamande S.A., Eltabbakh G.H., et al. First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix - A phase II study. Gynecol Oncol. 75:1999;334-337.
18. Lindegaard J.C., Grau C. Has the outlook improved for amifostine as a clinical radioprotector? Radiother Oncol. 57:2000;113-118.
19. van der Vijgh W.J., Peters G.J. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol) Preclinical aspects . Semin Oncol. 21:(5 Suppl. 11):1994;2-7.
20. Roeske J.C., Lujan A., Rotmensch J., et al. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 48:2000;1613-1621.
21. Mundt A.J., Roeske J.C., Lujan A.E., et al. Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol. 82:2001;456-463.
22. Mundt A.J., Lujan A.E., Rotmensch J., et al. Intensity modulated whole pelvic radiation therapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 52:2002;1330-1337.
23. Mundt A.J., Roeske J.C., Lujan A.E. Intensity modulated radiation therapy in gynecologic malignancies. Med Dosim. 27:2002;131-136.
24. Mundt A.J., Rotmensch J., Waggoner S., et al. Phase I trial of concomitant chemoradiotherapy for cervical cancer and other advanced pelvic malignancies. Gynecol Oncol. 72:1999;45-50.
25. Mundt A.J., Rotmensch J., Waggoner S.E., et al. Phase I trial of concomitant vinorelbine, paclitaxel, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies. Gynecol Oncol. 82:2001;333-337.
26. Sailer S.L., Chaney E.L., Rosemann J.G., et al. Treatment planning at the University of North Carolina at Chapel Hill. Semin Radiat Oncol. 2:1992;267-273.
27. Report number 50: Prescribing, recording, and reporting photon beam therapy. 1993;ICRU, Washington, DC.
28. Lujan A.E., Roeske J.C., Mundt A.J. Intensity-modulated radiation therapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiation therapy. [Abstract] Int J Radiat Oncol Biol Phys. 51:2001;220.
29. Zachariah B., Jacob S.S., Gwede C., et al. Effect of fractionated regional external beam radiotherapy on peripheral blood cell count. Int J Radiat Oncol Biol Phys. 50:2001;465-472.
30. Broun E.R., Iseminger K.A., Rose P.G., et al. A Phase II trial of edatrexate in previously treated squamous cell cervical cancer A Gynecology Oncology Group study . Am J Clin Oncol. 20:1997;78-80.
31. Coleman R.E., Clarke J.M., Slevin M.L., et al. A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix. Cancer Chemother Pharmacol. 27:1990;52-54.
32. Turbow M.M., Ballon S.C., Sikic B.I., et al. Cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced endometrial carcinoma. Cancer Treat Rep. 69:1985;465-467.
33. Rose P.G., Blessing J.A., Lewandowski G.S., et al. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma A Gynecology Oncology Group study . Gynecol Oncol. 63:1996;101-104.
34. Kaern J., Trope C., Sundfoer K., et al. Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma A phase II study with long-term follow-up . Gynecol Oncol. 60:1996;387-392.
35. Ball H.G., Blessing J.A., Lentz S.S., et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium A Gynecology Oncology Group study . Gynecol Oncol. 62:1996;278-281.
36. Thigpen T., Blessing J.A., Gallup D.G., et al. Phase II trial of mitomycin-C in squamous cell carcinoma of the uterine cervix A Gynecology Oncology Group study . Gynecol Oncol. 57:1995;376-379.
37. Burke T.W., Stringer C.A., Morris M., et al. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol. 40:1991;264-267.
38. Eisbruch A., Kim H.M., Terrell J.E., et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 50:2001;695-704.
39. Chao K.S., Deasy J.O., Markman J., et al. A prospective study of salivary function sparing in patient with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy Initial results . Int J Radiat Oncol Biol Phys. 49:2001;907-916.
40. Hong L., Hunt M., Chui C., et al. Intensity-modulated tangential beam irradiation of the intact breast. Int J Radiat Oncol Biol Phys. 44:1999;1155-1164.
41. Smitt M.C., Li S.D., Shostak C.A., et al. Breast-conserving radiation therapy Potential of inverse planning with intensity modulation . Radiology. 203:1997;871-876.
42. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 166:2001;876-881.
43. Teh B.S., Mai W.Y., Uhl B.M., et al. Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization Acute toxicity and dose-volume analysis . Int J Radiat Oncol Biol Phys. 49:2001;705-712.
44. Portelance L., Chao K.S., Grigsby P.W., et al. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys. 51:2001;261-266.
45. Chen Q., Izadifar N., King S., et al. Comparison of IMRT with 3-D CRT for gynecologic malignancies. [Abstract] Int J Radiat Oncol Biol Phys. 51:2001;332.
46. Selvaraj R.N., Gerszten K., King G.C., et al. Conventional 3-D versus intensity modulated radiotherapy for the adjuvant treatment of gynecologic malignancies A comparative study of dose-volume histograms and the potential impact on toxicities . [Abstract] Int J Radiat Oncol Biol Phys. 51:2001;218.
47. Kavanagh B.D., Schefter T.E., Wu Q., et al. Clinical application of intensity-modulated radiotherapy for locally advanced cervical cancer. Semin Radiat Oncol. 12:2002;260-271.
48. Ryan D.P., Compton C.C., Mayer R.J. Carcinoma of the anal canal. N Engl J Med. 342:2000;792-800.
49. Mundt A.J., Sibley G., Williams S., et al. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease. Int J Radiat Oncol Biol Phys. 33:1995;525-528.